Data from pivotal study of Marqibo in ALL patients to be presented at ASCO meeting

Download PDF Copy

Apr 23 2010

Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that complete data from its pivotal study of Marqibo® in patients with relapsed/refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL), have been accepted for an oral podium presentation at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 4-8, 2010 in Chicago, Illinois.

The oral podium presentation (Abstract #6507) entitled, "Phase II Study of Marqibo in Adult Patients with Refractory or Relapsed Philadelphia Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL)" will be presented in Room E354b at 11:45 a.m. on Monday, June 7.

SOURCE Hana Biosciences, Inc.

Posted in: Drug Trial News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

Most Americans unaware that early prostate cancer shows no symptoms

Dormant tumor cells targeted to reduce breast cancer relapse

Androgen deprivation therapy lowers satisfaction after penile prosthesis surgery

Plant-derived carotenoid found to boost immune response against cancer

Researchers identify genetic toolkit to reprogram cells into immune sentinels

Landmark study maps mutational landscape of triple-negative breast cancer in African American women

New drug dismantles cancer cell powerhouse to halt tumor growth

Study provides evidence for a causal genetic link between prostate cancer and urothelial carcinoma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.